Pfizer Inc (PFE) Up 0.87%

Pfizer Inc 4 Hour Price Update

Updated September 03, 2020 04:37 PM GMT (12:37 PM EST)

The price of PFE sunk $-0.66 (-1.76%) over the past four hours. For context, Pfizer Inc’s peers in the in the Pharmaceutical Products industry are down -4.38% on average in this time, while the broader Healthcare sector is down by an average of -3.77%.

Pfizer Inc Daily Price Recap

37.2 was the closing price of the day for Pfizer Inc, resulting in today being one in which price moved up 0.87% ($0.32) from the previous day. The price move occurred on volume that was down 19.66% from the day prior, but up 17.33% from the same day the week before. Let’s take a look at the daily price chart of Pfizer Inc.


Pfizer Inc Technical Analysis

Coming into today Pfizer Inc is now close to its 50, 100 and 200 day averages, located at 36.73, 36.59 and 36.56 respectively, and thus may be at a key juncture along those timeframes. Trend traders will want to observe that the strongest trend appears on the 14 day horizon; over that time period, price has been moving down. For another vantage point, consider that Pfizer Inc’s price has gone down 18 of the previous 30 trading days.

Overheard Around the Web

Over on StockTwits, here’s an example of what they’re saying about PFE:

    $PFE CEO confirms late-stage coronavirus vaccine trial may have results in October. They have already enrolled 23,000 volunteers in the phase three trial that began in late July & hopes to enroll at least 30,000 participants.

    Pfizer’s potential vaccine is one of three backed by the U.S. that’s currently in late-stage testing.

    “We expect by the end of October, we should have enough … to say whether the product works or not,”

    If it is successful, they plan to supply up to 100M doses by the end of 2020 and approximately 1.3B doses by the end of 2021.

    In July, the US govt announced it would pay Pfizer & $BNTX $1.95B to produce and deliver 100M doses of their vaccine if it proves safe and effective.

    Pfizer has made deal w/ Canada & the UK + in talks w/ the EU (issue: EU is only offering partial protection against legal liability from potential side effects)